FDA Approved: VIDAZA — Supplemental Application (Celgene Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Vidaza (azacitidine) submitted by Celgene Corporation, updating/adding to the product's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• VIDAZA (AZACITIDINE)

Snippet

SUPPL AP for VIDAZA (AZACITIDINE)